Cipla Limited — Exemestane Exporter Profile
Indian Pharmaceutical Exporter · #5 for Exemestane · $800.0K export value · DGFT Verified
Cipla Limited is the #5 Indian exporter of Exemestane with $800.0K in export value and 16 verified shipments. Cipla Limited holds a 5.5% market share in Exemestane exports across 3 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Exemestane Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Exemestane?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $444.9K | 10 | 72.2% |
| MEXICO | $169.7K | 5 | 27.6% |
| CHINA | $1.3K | 1 | 0.2% |
Cipla Limited exports Exemestane to 3 countries. The largest destination is UNITED STATES accounting for 72.2% of Cipla Limited's Exemestane shipments, followed by MEXICO (27.6%) and CHINA (0.2%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Exemestane from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $394.9K | 9 |
| ALTERNAVIDA SA DE | MEXICO | $100.0K | 2 |
| ALTERNAVIDA SA DE CV Y/O MOVERS SOL | MEXICO | $69.7K | 3 |
| CIPLA USA INC UPS SUPPLY CHAIN SOL | UNITED STATES | $50.0K | 1 |
| JIANGXI HUAYAO PHARMA CO LTD | CHINA | $1.3K | 1 |
Cipla Limited supplies Exemestane to 5 buyers globally. The largest buyer is CIPLA USA INC UPS SUPPLY CHAIN SOLU (UNITED STATES), followed by ALTERNAVIDA SA DE (MEXICO) and ALTERNAVIDA SA DE CV Y/O MOVERS SOL (MEXICO). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Exemestane Export Value and How Much Does Cipla Limited Contribute?
India exported $10.9M worth of Exemestane through 1,533 shipments from 87 suppliers to 57 countries, serving 196 buyers globally. Cipla Limited contributes $800.0K to this total, accounting for 5.5% of India's Exemestane exports. Cipla Limited ships Exemestane to 3 countries through 5 buyers.
What Is the Average Shipment Value for Cipla Limited's Exemestane Exports?
Cipla Limited's average Exemestane shipment value is $50.0K per consignment, based on 16 shipments totaling $800.0K. The largest destination is UNITED STATES (72.2% of Cipla Limited's Exemestane exports).
How Does Cipla Limited Compare to Other Indian Exemestane Exporters?
Cipla Limited ranks #5 among 87 Indian Exemestane exporters with a 5.5% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($4.5M), MSN LABORATORIES PRIVATE LIMITED ($1.7M), EUGIA PHARMA SPECIALITIES LIMITED ($1.4M). Cipla Limited processed 16 shipments to 3 destination countries.
What Exemestane Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| EXEMESTANE 25MG TABLETS NDC NO.69097-31 | $150.0K | 3 |
| EXEMESTANE TABLETS USP 25MG PACK SIZE: 1X 30S | $100.0K | 2 |
| EXEMESTANE 25MG TABLETS NDC NO. 69097-316-02 ANDA NO. 210323 (INV.QTY.19008PACK 1 X 30S =570240 NOS) | $94.9K | 3 |
| EXEMESTANE TABLETS USP 25MG (19344PACKS X 1X30'S=580320 NOS) | $69.7K | 3 |
| EXEMESTANE 25mg TABLETS NDC No 69097 316 02 ANDA No 210323 PACK SIZE 1X30X19320 PACK 579600 | $50.0K | 1 |
| EXEMESTANE 25MG TABLETS NDC NO 69097 316 02 ANDA NO 210323 19392 PACK X1X30S 581760 NOS | $50.0K | 1 |
| EXEMESTANE 25MG TABLETS NDC NO. 69097-316-02 ANDA NO. 210323 INV.QTY.19200PACK 1X30S=576000 NOS | $50.0K | 1 |
| EXEMESTANE 25MG TABLETS; NDC NO.69097-316-02; ANDA NO. : 210323 (19200 PACKS X 1X30'S=576000 NOS) | $50.0K | 1 |
| YIXITANE EXEMESTANE TABLETS 25 MG 168PACK x1X30 S 5040NUM | $1.3K | 1 |
Cipla Limited exports 9 distinct Exemestane formulations including tablets, capsules, syrups, and combination drugs. The top formulation is EXEMESTANE 25MG TABLETS NDC NO.69097-31 with 3 shipments worth $150.0K.
Regulatory Requirements: Exporting Exemestane to Key Markets
What Cipla Limited must comply with to export Exemestane to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Exemestane Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | EUGIA PHARMA SPECIALITIES LIMITED | $1.4M | 27 | 1 | $50.0K |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $900.0K | 18 | 4 | $50.0K |
| 5 | CIPLA LIMITED ★ | $800.0K | 16 | 3 | $50.0K |
| 6 | TITAN LABORATORIES PRIVATE LIMITED | $500.0K | 10 | 1 | $50.0K |
| 9 | INTAS PHARMACEUTICALS LTD | $355.9K | 13 | 4 | $27.4K |
Cipla Limited ranks #5 among 87 Indian Exemestane exporters. Average shipment value of $50.0K compared to the market average of $124.9K. The closest competitors by value are EUGIA PHARMA SPECIALITIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Exemestane Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 314 | 20.5% |
| DELHI AIR CARGO ACC (INDEL4) | 273 | 17.8% |
| SAHAR AIR | 256 | 16.7% |
| DELHI AIR | 128 | 8.3% |
| Bombay Air Cargo | 62 | 4.0% |
| MUNDRA SEA (INMUN1) | 52 | 3.4% |
| MUNDRA SEA | 51 | 3.3% |
| AHEMDABAD AIR ACC (INAMD4) | 50 | 3.3% |
Geopolitical & Trade Policy Impact on Cipla Limited's Exemestane Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Exemestane, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Exemestane — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Exemestane shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 16 individual customs records matching Cipla Limited exporting Exemestane, covering 9 formulations to 3 countries via 5 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 57+ countries, 196+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Exemestane Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Exemestane exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Exemestane Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Exemestane. For current shipment-level data, contact TransData Nexus.